Arcadia Biosciences, Inc.
RKDA
$0.92
-$0.11-10.85%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -8.33% | -25.90% | -15.29% | 11.41% | 21.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -8.33% | -25.90% | -15.29% | 11.41% | 21.58% |
| Cost of Revenue | 2.64% | 3.35% | -16.29% | 29.55% | 42.98% |
| Gross Profit | -22.78% | -63.77% | -13.10% | -6.18% | 1.57% |
| SG&A Expenses | -32.16% | -40.98% | -29.94% | -20.87% | -15.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.36% | -31.88% | -25.57% | -11.12% | -4.69% |
| Operating Income | 36.15% | 35.29% | 34.55% | 25.69% | 21.39% |
| Income Before Tax | -268.72% | 67.04% | 172.42% | -340.97% | 374.45% |
| Income Tax Expenses | -- | 0.00% | -- | -- | -- |
| Earnings from Continuing Operations | -268.72% | 66.91% | 172.42% | -340.97% | 374.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -268.72% | 67.13% | 153.10% | -520.17% | 207.26% |
| EBIT | 36.15% | 35.29% | 34.55% | 25.69% | 21.39% |
| EBITDA | 36.12% | 34.74% | 34.40% | 25.18% | 19.59% |
| EPS Basic | -210.65% | 67.29% | 152.97% | -518.90% | 206.92% |
| Normalized Basic EPS | -319.95% | 65.90% | 172.24% | -153.08% | 192.90% |
| EPS Diluted | -211.05% | 67.17% | 152.31% | -1,076.96% | 206.50% |
| Normalized Diluted EPS | -319.95% | 65.90% | 172.00% | -210.26% | 192.90% |
| Average Basic Shares Outstanding | 52.47% | 0.51% | 0.25% | 0.31% | 0.32% |
| Average Diluted Shares Outstanding | 52.46% | 0.51% | 0.59% | -18.18% | 0.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |